Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)Ryan B. Corcoran, Eric Van Cutsem, Chloé E. Atreya et al.|Annals of Oncology|2016Cited by 46
LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)Eric Van Cutsem, Ryan B. Corcoran, Chloé E. Atreya et al.|Annals of Oncology|2015Cited by 23